SCHEMBL5547002

SCHEMBL5547002

CC(C)Cn1c(=O)c(C(=O)Nn2cnnc2)c(O)c2ncc(Cc3ccc(F)cc3)cc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
HSD17B10 Q99714 1/20 0.43
CNR2 P34972 5/20 0.41
LMNA P02545 7/20 0.40
SMN1; SMN2 Q16637 5/20 0.40
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
HTT P42858 5/20 0.39
TSHR P16473 4/20 0.39
USP2 O75604 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
KDM4E B2RXH2 5/20 0.39
HPGD P15428 1/20 0.39
HSP90AA1 P07900 1/20 0.39
ALOX15 P16050 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
GAA P10253 2/20 0.37
MAPT P10636 3/20 0.36
RECQL P46063 1/20 0.35
CNR1 P21554 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545869 0.85 ALDH1A1 (0.42) ALDH1A1HSD17B10CNR2LMNASMN1; SMN2
SCHEMBL15163642 0.85 ALDH1A1 (0.44) ALDH1A1HSD17B10CNR2LMNASMN1; SMN2
SCHEMBL5546924 0.85 ALDH1A1 (0.43) ALDH1A1HSD17B10CNR2LMNASMN1; SMN2
SCHEMBL5540178 0.84 ALDH1A1 (0.43) ALDH1A1HSD17B10CNR2LMNASMN1; SMN2
SCHEMBL5545945 0.83 ALDH1A1 (0.42) ALDH1A1HSD17B10CNR2LMNASMN1; SMN2
SCHEMBL5538837 0.81 KDM4E (0.41) ALDH1A1HSD17B10CNR2LMNASMN1; SMN2
SCHEMBL5546863 0.81 CNR2 (0.41) ALDH1A1HSD17B10CNR2LMNASMN1; SMN2
SCHEMBL5547394 0.81 CNR2 (0.42) ALDH1A1HSD17B10CNR2LMNASMN1; SMN2
SCHEMBL5546543 0.79 ALDH1A1 (0.41) ALDH1A1HSD17B10CNR2LMNASMN1; SMN2
SCHEMBL15163675 0.78 CNR2 (0.46) ALDH1A1HSD17B10CNR2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 ALDH1A1 3812/4885HSD17B10 2218/4885CNR2 3954/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 ALDH1A1 3073/4885HSD17B10 1401/4885CNR2 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.